A Trial of PT2977 in Combination With Cabozantinib in Patients With Clear Cell Renal Cell Carcinoma (ccRCC)

Conditions:   RCC;   Clear Cell Renal Cell Carcinoma;   Kidney Cancer;   Renal Cancer;   Renal Cell Carcinoma;   Renal Cell Cancer Metastatic;   Renal Cell Carcinoma Recurrent;   Renal Cell Cancer, Recurrent;   Kidney Intervention:   Drug: PT2977 in combination with cabozantinib tablets Sponsor:   Peloton Therapeutics, Inc. Not yet recruiting
Source: ClinicalTrials.gov - Category: Research Source Type: clinical trials